Business
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando.
About this update from United Therapeutics Corporation
[{"type":"text","content":"Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) include efficacy and safety results from TETON-1 and integrated results from TETON-1 and TETON-2","length":232,"tagName":"p"},{"type":"text","content":"Results from the successful ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension (PAH) will be presented","length":122,"tagName":"p"},{"type":"text","content":"Additional presentations include an interim analysis from the TETON-PPF study of inhaled treprostinil in progressive pulmonary fibrosis (PPF), preliminary results from the PHINDER study of patients with interstitial lung disease (ILD) with and without pulmonary hypertension (PH), and interim results from the ARTISAN study of parenteral treprostinil in PAH","length":357,"tagName":"p"},{"type":"text","content":"SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 11, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando.","length":364,"tagName":"p"},{"type":"text","content":""We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieved unprecedented results in these two life-threatening diseases that have significant unmet needs. The data we are sharing from our research programs in pulmonary hypertension and ILD, including PHINDER, ARTISAN, and TETON-PPF, will also provide important clinical insights that may meaningfully impact how these devastating diseases are managed and help improve outcomes for the people living with them," said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics.","length":657,"tagName":"p"},{"type":"text","content":"Poster Presentations Include:","length":29,"tagName":"p"},{"type":"text","content":"ARTISAN Interim Analysis: Early Treatment with High-Dose Treprostinil Reduces Mean Pulmonary Artery Pressure and Improves Risk Status in Pulmonary Arterial Hypertension, Oral Session AQ19, Sunday, May 17, 9:27 - 9:39 am","length":219,"tagName":"p"},{"type":"text","content":...